Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ray-Coquard, Isabelle, Italiano, Antoine, Bompas, Emmanuelle, Le Cesne, Axel, Robin, Yves-Marie, Chevreau, Christine, Bay, Jacques-Olivier, Bousquet, Guilhem, Piperno-Neumann, Sophie, Isambert, Nicolas, Lemaitre, Laurent, Fournier, Charles, Gauthier, Eric, Collard, Olivier, Cupissol, Didier, Clisant, Stéphanie, Blay, Jean-Yves, Penel, Nicolas
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2012
Pynciau:
Sarcomas
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/
https://ncbi.nlm.nih.gov/pubmed/22285963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg